BRL-302 / BRL Medicine - LARVOL DELTA

Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC (clinicaltrials.gov) - P1 | N=3 | Recruiting | Sponsor: Shanghai Changzheng Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC (clinicaltrials.gov) - P1 | N=3 | Not yet recruiting | Sponsor: Shanghai Changzheng Hospital

New P1 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. (clinicaltrials.gov) - P1 | N=25 | Not yet recruiting | Sponsor: Xuanwu Hospital, Beijing | Initiation date: Aug 2024 ➔ Feb 2025

Trial initiation date • CNS Disorders • Immunology • Multiple Sclerosis • Myasthenia Gravis • Neuromyelitis Optica Spectrum Disorder • Pain • Rare Diseases

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Bioray Laboratories

CAR T-Cell Therapy • New P1 trial • CNS Disorders • Immunology • Neuromyelitis Optica Spectrum Disorder • Rare Diseases

Cost-Effectiveness and Budget Impact Analyses Using Real World Data from Brazilian Health Care Insurance Companies in the Treatment of Iron Deficiency in Patients with Heart Failure (ISPOR-EU 2023) - "The weekly outpatient cost was NYHA I (BRL 81.01), NYHA II (BRL 84.20), NYHA III (BRL302.88), NYHA IV (BRL269.36) The Incremental Cost Effectiveness Ratio (ICER) was dominant BRL 2.675,29/QALY... The algorithm used for clustering was effective and showcased a substantive savings of BRL 36.380.871 over 5 years. Ferric Carboximaltose proved to be a cost- effective option with an ICER below the Brazilian threshold of BRL 30-40K/QALY."

Clinical • Cost effectiveness • HEOR • Real-world • Real-world evidence • Reimbursement • US reimbursement • Cardiovascular • Congestive Heart Failure • Critical care • Heart Failure • Hematological Disorders